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ABSTRACT
Purpose. We assessed molecular (presence of melanoma
cells markers in lymph ﬂuid [LY]) and pathological fea-
tures (sentinel lymph node [SN] tumor burden according to
Rotterdam criteria, metastases microanatomic location) and
correlated them with survival and melanoma prognostic
factors in a group of patients with positive SN biopsy.
Methods. We analyzed 368 consecutive SN-positive
patients after completion lymph node dissection (CLND).
In 321 patients we obtained data on SLN microanatomic
location/tumor burden (only 7 cases had metastases
\0.1 mm); in 137 we additionally analyzed 24-hour col-
lected LY after CLND (multimarker reverse transcriptase-
polymerase chain reaction [MM-RT-PCR] with primers for
tyrosinase, MART1 (MelanA), and uMAGE mRNA (27.7%
positive samples)]. Median follow-up time was 41 months.
Results. According to univariate analysis, the following
factors had a negative impact on overall survival (OS):
higher Breslow thickness (P = .0001), ulceration (P\
.0001), higher Clark level (P = .008), male gender
(P = .0001), metastatic lymph nodes [1( P\.0001),
nodal metastases extracapsular extension (P\.0001),
metastases to additional non-SNs (P = .0004), microme-
tastases size C0.1 mm (P = .0006), and positive LY MM-
RT-PCR (P = .0007). SN tumor burden showed linear
correlation with increasing Breslow thickness (P = .01).
The 5-year OS rates for SLN tumor burden \0.1 mm, 1–
1.0 mm, and [1.0 mm were 84%/66%/44%, respectively,
and for positive and negative LY MM-RT-PCR 47%/0%,
respectively. The independent factors for shorter OS
(multivariate analysis): male gender, primary tumor
ulceration, number of involved nodes C4, micrometastases
size [1.0 mm, and, in additional model including molec-
ular analysis—positive MM-RT-PCR results (hazard ratio
[HR] 3.2), micrometastases size[1.0 mm (HR 1.13), and
primary tumor ulceration (HR 2.17). Similar results were
demonstrated for disease-free survival (DFS) data.
Conclusions. SN tumor burden categories according to
Rotterdam criteria and the positive result of LY MM-RT-
PCR assay demonstrated additional, independent prognos-
tic value in SN-positive melanoma patients, showing
signiﬁcant correlation with shorter DFS and OS.
Sentinel node biopsy (SNB) is currently a valuable and
reliable diagnostic procedure for precise staging of cuta-
neous melanoma patients with clinically noninvolved
regional nodes.
1–4 In case of positive sentinel node biopsy
the radical removal of lymph nodes of involved basin is
indicated. The new 2010 American Joint Committee on
Cancer (AJCC) cutaneous melanoma staging system con-
ﬁrmed the value of sentinel lymph node biopsy (SNB) as
minimally invasive surgical procedure for microstaging of
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5 The
AJCC and our previous analysis conﬁrmed that the features
of nodal metastases (number of involved nodes) and pri-
mary tumor features (e.g., presence of ulceration, tumor
Breslow thickness) have the impact on patient outcome
after completion lymph node dissection (CLND) due to
positive SNB.
5,6 However, current prognostic factors are
still inadequate for precise guide of the treatment, because
of the high heterogeneity of SNB-positive patients. Recent
discoveries have stressed the prognostic role of SN tumor
burden and microanatomic tumor deposit location.
7–9 Van
Akkooi et al. showed that submicrometastases \0.1 mm
according to the Rotterdam criteria have extremely favor-
able prognosis identical to patients with negative SNs.
7,8
Additional disease-speciﬁc factors can provide molec-
ular techniques. We have demonstrated previously with
using two-marker or multimarker reverse transcriptase-
polymerase chain reaction (MM RT-PCR) technique in the
group of cutaneous melanomas with regional node metas-
tases (microscopic and macroscopic), that positive result of
this assay correlated signiﬁcantly with early melanoma
recurrence and shorter survival.
10–12
The aim of the present study was to assess the role of
these new molecular and pathologic prognostic factors and
correlate them with other clinical-pathological factors and
survival data in group of cutaneous melanoma SN-positive
patients after CLND, treated in 1 institution.
PATIENTS AND METHODS
Patient Characteristics
We analyzed the data of 368 consecutive patients with
histologically conﬁrmed cutaneous melanoma, who
underwent radical lymph node dissection (CLND) at the
Department of Soft Tissue/Bone Sarcoma and Melanoma
at the Maria Sklodowska-Curie Memorial Cancer Centre
and Institute of Oncology, Warsaw, Poland (CCIO)
between May 1995 and February 2009 because of positive
SNB. The detailed technique of SNB and the pathologic
examination of SNs have been already presented in our
previous publications.
4 The false-negative cases (deﬁned as
nodal recurrence after initially negative SLN biopsy in the
biopsied basin) were excluded from the CLND group. The
margin of excision of all the primaries was C1 cm. Each
patient provided written informed consent. The study was
approved by the local Bio-Ethics Committee according to
Good Clinical Practice Guidelines.
All patients undergoing SNB had primary cutaneous
melanoma after excisional biopsy with Breslow thickness
C0.75 mm or ulcerated or Clark level CIV (all histological
diagnoses were conﬁrmed in the Department of Pathology
CCIO) with clinically nonpalpable regional lymph nodes
and without distant metastases.
The patients had not undergone any other preliminary
selection. Only patients who met with all the conditions
listed previously were enrolled in the study.
The clinicopathological stage of the melanoma patients
was determined by pathological evaluation of the primary
lesion and of the dissected lymph nodes, as well as by
physical examination and routine imaging examinations
(chest X-ray, ultrasound of the abdominal cavity, and
computed tomography imaging, if necessary).
Patients’ characteristics are summarized in Table 1. All
patients had conﬁrmed primary cutaneous melanoma.
Radical lymph node dissections were performed according
to the technique described by Karakousis.
13 For ilioingui-
nal lymphadenectomy we routinely excised the superﬁcial
and deep levels below the inguinal ligament to the level of
the aortic bifurcation combined with obturatory lymph
node dissection. A total of 82 patients received interferon-
a2b as adjuvant treatment after lymphadenectomy in
accord with the EORTC 18952 trial (without signiﬁcant
inﬂuence on survival data).
14
All patients were followed carefully with a median
follow-up time of 41 months for survivors (range, 6–
120 months). Postoperative follow-up consisted of physical
examination and routine imaging investigations (chest X-
ray, ultrasound of the abdominal cavity). Routinely, sur-
veillance was recommended every 3 months for the ﬁrst
2 years, every 4 months in year 3, every 6 months for years
4–5, and thereafter annually.
Pathological Examination
A total of 321 cases of pathological slides of the SNs
were re-evaluated for the purpose of this study [by AA,
WM]. It was performed according to the EORTC pathol-
ogy protocol developed by Cook et al., but only H&E
staining was performed ﬁrst.
15 If this was negative, other
slides were stained with S100 and HMB-45. The amount of
SN tumor burden was measured according to the Rotter-
dam criteria, which consist of the following: measure the
maximum diameter (in any direction) of the largest lesion
on a slide.
7 All positive slides are examined, and this
process of measuring the largest lesion is repeated. The
largest value overall (which is the largest diameter mea-
sured anywhere on 1 slide in 1 patient) has been deﬁned as
the amount of SN tumor burden (in mm). If a patient had
multiple positive SNs, the largest maximum diameter of
any of the SNs is the largest overall and thus the amount of
SN tumor burden for this patient. Categories were made for
SN tumor burden as follows:\0.1 mm (submicrometasta-
ses), 0.1–1.0 mm, and[1.0 mm.
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according to the Dewar criteria for the microanatomic
location of the metastasis.
9 This was either: subcapsular,
parenchymal, combined, multifocal, or extensive.
Lymph Fluid Preparation, RNA Isolation and RT-PCR
Methods
The lymph ﬂuid samples (usually 50–100 ml) were
collected in 137 patients in 24–72 h after the radical
lymphadenectomy (CLND) from routinely used sucking,
postoperative drainages. As soon as possible after collec-
tion, the samples were centrifuged (500g, 10 min) and
incubated with red blood cell-lysing solution for 10 min on
ice. The samples were centrifuged again, and the pellets
were collected. Total cellular RNA was prepared from
fresh or frozen pellets as described previously.
12 RNA was
further puriﬁed from trace amounts of DNA according to
the method recommended by the DNase I (RNase-free)
producer (Gibco-BRL), except that one-fourth of the
TABLE 1 Patient characteristics and distribution of clinicopatho-
logical features in all CLND patients
N %
Gender
Female 192 52.2
Male 176 47.8
Age (years)
\40 75 20.4
40–60 185 50.3
C60 108 29.3
Mean/median 51/52
Primary tumor site
Head/neck 1 0.3
Upper extremity 54 14.7
Lower extremity 130 35.3
Anterior trunk 49 13.3
Posterior trunk 134 36.4
Primary melanoma Breslow thickness (mm)
B 1.0 24 6.7
1.01–2.0 46 12.8
2.01–4.0 127 35.5
[4.0 161 45.0
Data not available 10
Median 4
Primary melanoma level of invasion according to Clark
II 24 6.7
III 122 34.1
IV 158 44.1
V 54 15.1
Data not available 10
Ulceration of melanoma
No 112 32.3
Yes 235 67.7
Data not available 21
Pathological type
NM 205 66.6
SSM 76 24.6
ALM 12 3.9
LMM 15 4.9
Data not available 60
Location of lymph node dissection
Neck 1 0.3
Axillary 212 57.7
Inguinal 152 41.3
Other/mixed 3 (axillary-inguinal) 0.7
Number of lymph nodes with metastases
1 205 56.0
2–3 125 34.2
C4 36 9.8
Data not available 2
TABLE 1 continued
N %
Extracapsular extension of lymph node metastases
No 284 77.2
Yes 84 22.8
Metastases to sentinel nodes only
Yes 262 71.6
No 104 28.4
Data not available 2
Maximal diameter of metastases to sentinel node
a
\0.1 mm 7 2.2
0.1–1.0 mm 105 32.7
[1.0 mm 209 65.1
Microanatomic localization of metastases in SN
a
Subcapsular 18 5.6
Combined 149 46.4
Parenchymal 67 20.9
Multifocal 15 4.7
Extensive 72 22.4
Lymph MM RT-PCR assay result
b
Positive 38 27.7
Negative 99 72.3
CLND group patients with regional lymph nodes metastases detected
by sentinel lymph node biopsy followed by completion lymph node
dissection, NM nodular melanoma, SSM superﬁcial spreading mela-
noma, ALM acral lentiginous melanoma, LMM lentigo malignant
melanoma, SN sentinel lymph node, MM RT–PCR multimarker
reverse-transcriptase polymerase chain reaction
a 321 patients
b 137 patients
3316 P. Rutkowski et al.recommended amount of DNase I was used. DNase I was
inactivated by 10-min incubation at 65C and phenol
extraction. RNA concentrations were determined spectro-
photometrically. RNA from the human melanoma cell line
MeW151 and from normal and fetal ﬁbroblast lines was
isolated as described by Chomczynski and Sacchi.
16 Before
cDNA synthesis, the integrity of each RNA sample was
checked by electrophoresis on a denaturing agarose gel. No
obvious degradation of the 28S and 18S RNA bands was
noted. The DNA contamination in RNA preparations were
checked in PCR assay with human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH 1 and GAPDH 2)
primers and RNA as template. The quality of cDNA was
controlled by PCR, with GAPDH 1, GAPDH 2 primers.
The Multi-marker [HTYR, MART1/MelanA, and uni-
versal melanoma antigen gene (uMAGE)] RT-PCR assay
was carried out as described previously, with minor mod-
iﬁcations.
10,11 For reverse transcription, 2 lg RNA was
used. The primer sequences and PCR conditions for HTYR
and MART1/MelanA ampliﬁcation and for uMAGE
ampliﬁcation were described in Ruka et al. and in Miyas-
hiro et al., respectively.
10,17 The solution was
supplemented with the remaining RT reagents and Super-
Script reverse transcriptase to a ﬁnal volume of 20 ll,
according to the conditions recommended by the manu-
facturer (Gibco-BRL). The reaction mixture was incubated
at 37C for 1 h. The cDNA product was further puriﬁed by
phenol/chloroform extraction and precipitation with 2.5
volumes of ethanol. The precipitated pellet was dissolved
in 15 ll DEPC-treated water. The resulting ampliﬁcation
products (10 ll) were analyzed by electrophoresis on a 2%
agarose gel, with DdeI-digested pUC 19 as a molecular
weight standard. The positive control in each experiment
was cDNA from melanoma cell line MeW151, which is
known to express each of the 3 markers.
The lymphatic drainage sample was deemed positive for
the presence of melanoma cells if at least 1 melanoma
marker was detected by MM RT-PCR. The researchers
who performed the PCR assay were blinded to disease
status, and those recording the disease status were blinded
to the PCR assay results.
Statistical Analyses
All statistical analyses were performed using R 2.10.1
statistical program (R Development Core Team;
http://www.R-project.org). Contingency tables were ana-
lyzed by the chi-square test. Correlation between primary
tumor Breslow thickness and SN metastases size was
analyzed with use of Spearman correlation coefﬁcient. For
comparison of 2 groups with non-normal distribution
nonparametric the Mann–Whitney U test was applied.
For the survival analysis the Kaplan–Meier estimator
was used with the log-rank tests for bivariate comparisons.
Overall survival (OS) time for the assessment of prognostic
value of clinical and pathological parameters was calcu-
lated from the date of lymph node dissection (CLND) to
the date of the most recent follow-up (censored data) or
death (as it was evaluated in the melanoma AJCC staging
system).
5,18,19 Similarly, disease-free survival time (DFS)
was calculated from the date of therapeutic lymphadenec-
tomy to the date of the most recent follow-up or disease
recurrence.
Clinical and pathological parameters as follow: gender,
age (\40 vs. 40–60 vs.[60 years), primary tumor Breslow
thickness (B1.0 vs. 1.01–2.0 vs. 2.01–4.0 vs. [4.0 mm),
presence of ulceration of primary lesion, primary tumor
level of invasion according to Clark (II/III vs. IV/V),
localization of lymphadenectomy (inguinal vs. axillary),
number of lymph nodes with metastases (1 vs. 2–3 vs. C4),
presence of extracapsular invasion in involved lymph
nodes, size of metastases to SN according to Rotterdam
criteria, microanatomic location of the metastasis and
result of lymph ﬂuid MM RT-PCR were tested as a factors
affecting patients survival. We have not analyzed the
prognostic signiﬁcance of multiple markers as compared
with single markers in lymph ﬂuid MM RT-PCR, because
of limited number of cases with positive multiple markers.
In the course of the multivariate analysis of the factors
associated with shortened survival time, we used Cox’s
proportional hazard models, applying the stepwise (for-
ward) model building procedure, including all covariates
signiﬁcant at 20% level in bivariate analysis. Because of
the limited number of patients (137), in whom the post-
operative lymph ﬂuid was analyzed with MM RT-PCR, 2
models for multivariate analysis were constructed: I with-
out MM RT-PCR results, and II including RT-PCR results.
The differences were considered statistically signiﬁcant
if the P values were\.05.
RESULTS
RT-PCR and Clinical-Pathological Results
Positive results for the MM RT-PCR assay were recor-
ded in 38 of 137 analyzed lymph ﬂuid specimens (27.7%).
Positive results for the RT-PCR assay correlated with a
higher Breslow thickness (P\.01), the higher number of
metastatic regional lymph nodes (P = .01) and an older
patients age (P\.05). A signiﬁcantly higher rate of
recurrence was observed in patients with positive RT-PCR
results (27 of 38 cases, 71.1%) than in those with negative
results (49 of 99 cases, 49.5%; P = .02). The pattern of the
ﬁrst recurrences in the MM RT-PCR patients was: 18
Molecular and Pathological Factors in Melanoma Positive Sentinel Node 3317cases, distant metastases (66.7%; mainly lungs); 8, in-
transit/local recurrences 29.6%); and 1, the same nodal
basin recurrence (3.7%).
The distribution of SN tumor burden according the
Rotterdam criteria was (Table 1): \0.1 mm, 7 cases
(2.2%); 0.1–1.0 mm, 105 cases (32.7%); and [1.0 mm,
209 cases (65.1%). The SN tumor burden showed linear
correlation with increasing Breslow thickness (P = .01;
correlation coefﬁcient r = 0.15). The rate of additional
non-SN involvement according to Rotterdam criteria for
SN tumor burden increased from 0% in submicrometasta-
ses (\0.1 mm) through 18% (0.1–1.0 mm) to 30.6% in SN
metastases[1.0 mm (P\.01) (Table 2).
Survival Analysis
The median OS and 5-year OS rates were: 59.2 months
and 51.5% (95% conﬁdence interval [95% CI]: 44.9%–
59.9%), respectively; and the median DFS and 5-year rates
were: 29.7 months and 40.5% (95% CI: 34.5%–47.8%),
respectively.
The results of univariate analysis of the impact of
individual factors on OS and DFS (calculated from the date
of lymph node dissection) are shown in Table 3.
According to the univariate analysis, the following
factors had a negative impact on overall survival of patients
after CLND: higher primary tumor Breslow thickness,
ulceration of primary tumor, higher level of invasion in
primary melanoma according to Clark, male gender,
number of lymph node with metastases [1, extracapsular
extension of nodal metastases, axillary location of nodal
metastases, presence of metastases to additional non-SNs,
maximal SN tumor burden C0.1 mm (Fig. 1a) and positive
result of lymph ﬂuid MM RT-PCR (Fig. 1b).
The following factors had a negative impact on disease-
free survival according to the univariate analysis: male
gender, higher primary tumor Breslow thickness, higher
level of invasion in primary melanoma according to Clark,
ulceration of primary tumor, number of lymph nodes with
metastases [1, extracapsular extension of nodal metasta-
ses, presence of metastases to additional non-SNs, maximal
SN tumor burden C0.1 mm and positive result of lymph
ﬂuid MM RT-PCR.
According to the multivariate analysis, we have con-
ﬁrmed and identiﬁed that the most important factors
negatively inﬂuencing OS are: in model I (without results
of lymph MM RT-PCR)—male gender (HR = 2.004; 95%
CI = 1.348–2.976; P = .001), features of primary tumor
[presence of ulceration (HR = 2.168; 95% CI = 1.35–
3.48; P = .001)], and features of nodal metastases [SN
tumor burden [1.0 mm (HR = 1.06; 95% CI = 1.014–
1.11; P = .010) and number of involved nodes [1
(P\.0001)]; and in model 2 (including results of lymph
MM RT-PCR)—presence of ulceration of primary mela-
noma (HR = 2.17; 95% CI = 1.12–4.2; P = .021), SN
tumor burden [1.0 mm (HR = 1.13; 95% CI = 1.05–
1.21; P = .001)] and positive result of lymph ﬂuid MM
RT-PCR (HR = 3.24; 95% CI = 1.76–5.95; P\.001)
(Table 4).
Negative impact on DFS according to multivariate
analysis had the following factors: in model I—male gen-
der (HR = 1.46; 95% CI = 1.017–2.092; P = .04),
features of primary tumor [higher Breslow thickness
[1.0 mm (P = .019), higher level of invasion according to
Clark (P = .013), and presence of ulceration (HR = 1.955;
95% CI = 1.26–3.04; P = .003)], and features of nodal
metastases [number of involved nodes [1( P\.0001)];
and in model 2—presence of ulceration of primary mela-
noma (HR = 2.33; 95% CI = 1.32–4.27; P = .006), SN
tumor burden [1.0 mm (HR = 1.07; 95% CI = 1.006–
1.144; P = .032), number of involved nodes [1
(P = .023), and positive result of lymph ﬂuid MM RT-
PCR (HR = 2.23; 95% CI = 1.27–3.9; P = .005)
(Table 5).
DISCUSSION
The presence of nodal metastases in patients with pri-
mary cutaneous melanoma is the most important factor that
adversely affects the biological behavior and is related to
poor prognosis.
1–4,20,21 Sentinel node biopsy is perhaps the
greatest contribution in surgical oncology of last 2 decades
for assessment of the stage of regional nodes.
22 Along with
the more extensive pathological protocols of sentinel node
examinations (using serial sectioning and immunohisto-
chemistry) SNB is currently the most powerful technique
for the identiﬁcation of micrometastases to regional lymph
nodes.
23,24 There is a worldwide agreement about the
negative prognostic implications of node positivity in
cutaneous melanoma, but the clinical signiﬁcance of tiny
tumor deposits is still debatable. We have conﬁrmed in our
group of patients that the Rotterdam criteria for assessment
of tumor burden in SNs gives the independent prognostic
information and may in the future replace other factors
related to nodal metastases (as number of metastatic nodes
or extracapsular involvement—the factors, which
TABLE 2 Correlation of sentinel node tumor burden according to
Rotterdam criteria and presence of metastases to nonsentinel nodes
Sentinel node
tumor burden
No additional
nonsentinel nodes
involvement
Additional
nonsentinel
nodes involvement
\0.1 mm 7 (100%) 0 (0%)
0.1–1.0 mm 86 (81%) 19 (19%)
[1.0 mm 146 (69%) 63 (31%)
3318 P. Rutkowski et al.independent signiﬁcance was conﬁrmed in our previous
analysis not including SN deposit size).
6 The group of
patients with submicrometastases \0.1 mm, although
responsible for only 2.2% of positive SNs in our group of
patients (what might be related to rather high median
Breslow thickness of primaries and explained by
TABLE 3 The 5-year overall
survival (OS) and disease-free
survival (DFS) rate in group
after completion lymph node
dissection (CLND) because of
positive sentinel nodes
according to clinical-
pathological and molecular
features of primary tumor and
nodal metastases (calculated
from the date of CLND)
CLND group patients with
regional lymph nodes
metastases detected by sentinel
lymph node biopsy followed by
completion lymph node
dissection, SN sentinel lymph
node, MM RT-PCR multimarker
reverse-transcriptase
polymerase chain reaction, NA
not available
5-year OS rate
(95% conﬁdence interval)
P value 5-year DFS rate
(95% conﬁdence interval)
P value
Primary melanoma Breslow thickness (mm)
B1.0 77.8 (54.9–100) .0001 39.6 (10.0–87.5) .0001
1.01–2.0 68.6 (51.2–91.8) 58.7 (40.9–84.4)
2.01–4.0 60.5 (50.2–73.0) 51.3 (41.0–64.2)
[4.0 38.7 (31.7–47.3) 29.5 (23.0–37.7)
Ulceration of melanoma
No 66.8 (56.9–78.4) \.0001 54.5 (44.5–66.7) .0000
Yes 39.6 (32.7–47.9) 29.0 (22.5–37.2)
Primary melanoma level of invasion according to Clark
II–III 57.6 (33.8–81.2) .0083 48.5 (13.1–69.0) .0009
IV–V 39.5 (27.5–56.8) 28.5 (17.5–43.8)
Location of lymph node dissection
Axillary 42.6 (35.7–51.6) .0098 34.1 (27.2–42.7) .11
Inguinal 58.6 (50.0–68.7) 44.7 (36.2–55.2)
Gender
Female 58.9 (51.2–67.7) .0001 42.6 (35.1–51.8) .04
Male 33.6 (25.6–44.1) 29.1 (21.4–39.5)
Age (years)
\40 58.2 (46.8–72.4) .2054 48.6 (37.2–63.5) .11
40–60 48.1 (33.9–62.5) 34.8 (19.3–54.2)
C60 39.8 (17.4–63.5) 35.4 (23.8–62.2)
Number of lymph nodes with metastases
1 59.6 (52.3–67.9) \.0001 50.1 (42.7–58.8) \.0001
2–3 36.5 (27.7–47.9) 26.3 (18.6–37.2)
C4 29.3 (15.2–56.5) 11.8 (3.7–38.0)
Extracapsular extension of lymph nodes metastases
No 53.5 (47.1–60.8) \.0001 42.2 (35.9–49.6) \.0001
Yes 26.9 (16.7–40.7) 18.6 (10.8–32.2)
Metastases to additional non-SNs
Absent 55.9 (46.9–72.3) .0004 48.7 (35.8–55.4) \.0001
Present 32.5 (26.3–48.5) 21.4 (12.5–37.2)
Maximal diameter of metastases to sentinel node
\0.1 mm 83.8 (58.3–100.0) .0006 83.3 (58.3–100.0) .004
0.1–1.0 mm 66.2 (55.6–78.8) 55.2 (44.5–68.5)
[1.0 mm 40.2 (33.1–48.8) 30.0 (23.5–38.4)
Microanatomic localization of metastases in SN
Subcapsular 43.6 (25.1–75.6) .07 38.0 (21.7–66.3) .2734
Combined 65.8 (52.6–82.2) 42.0 (29.7–59.4)
Parenchymal 59.5 (48.3–73.2) 45.0 (33.7–60.0)
Multifocal 39.4 (30.8–50.3) 34.1 (26.0–44.9)
Extensive 41.2 (28.1–60.3) 26.5 (14.5–48.3)
Lymph MM RT-PCR assay result
Positive 46.7 (36.3–59.9) .0007 39.0 (29.0–52.4) .005
Negative 0 (NA–NA) 21.1 (10.5–42.4)
Molecular and Pathological Factors in Melanoma Positive Sentinel Node 3319demonstrated in our analysis existing the linear correlation
between primary tumor thickness and SN tumor deposit
size), was characterized by excellent prognosis with 5-year
OS exceeding 80%. Moreover, we have conﬁrmed that, the
tumor burden assessed by these criteria is closely associ-
ated with the presence of metastases to additional non-SNs
after CLND, what has been suggested previously.
7,8,25,26
The presence of positive non-SNs is per se highly negative
prognostic factor for patient survival analyzed recently by
other authors.
27,28
The other important result of our study is the conﬁr-
mation of the important prognostic impact of the MM RT-
PCR assay proposed by us for assessment of the presence
of melanoma molecular markers in lymph ﬂuid collected
routinely after lymph node dissection.
10–12 In the
multivariate analysis model including the results of lymph
MM RT-PCR, we have demonstrated that positive result of
this assay is the most important independent prognostic
factor (beyond the primary tumor ulceration and SN tumor
burden according to Rotterdam criteria) for poor survival in
group of patients limited to SN-positive cases. The results
of RT-PCR analyses of melanoma circulating cells in blood
specimens (especially from single, not serial determination
studies) and of detection of melanoma molecular markers
in SNs are controversial.
29–47 The analysis of lymph MM
RT-PCR gave more consistent data, which may be related
to high volume of lymph ﬂuid in patients with conﬁrmed
lymphatic dissemination of the disease (in the blood tumor
cells may be present at extremely low concentrations and
tumor shedding may be intermittent) and using multiple
a b FIG. 1 Overall survival
(calculated from the date of
lymphadenectomy) in the group of
patients after completion lymph
node dissection for regional
lymph nodes metastases detected
by sentinel lymph node biopsy
according to a sentinel node
tumor burden (Rotterdam criteria)
(P = .0006) and b the results of
lymph ﬂuid multimarker RT-PCR
assay (P = .0007)
TABLE 4 Summary of the multivariate analysis of selected factors associated with overall survival (model 1, without results of lymph MM RT-
PCR; model 2, including results of lymph MM RT-PCR)
Variable Model 1 (N = 321) Model 2 (N = 137)
P value HR HR 95% CI P value HR HR 95% CI
Gender
Male vs. female .001 0.499 0.336-0.742
Primary melanoma level of invasion according to Clark
Clark III .216 0.580 0.245-1.374
Clark IV .574 1.266 0.557-2.875
Clark V .871 0.929 0.380-2.272
Ulceration of melanoma
Present vs absent .001 2.168 1.349-3.483 .021 2.17 1.124-4.201
Maximal diameter of metastases to sentinel node
[1.0 mm versus 0.1–1.0 mm .010 1.061 1.014-1.110 .001 1.128 1.053-1.209
Number of lymph nodes with metastases
2–3 .111 1.409 0.924-2.147
C4 .006 2.692 1.328-5.453
Lymph MM RT-PCR assay result
Positive vs. negative \.001 3.24 1.78-5.95
HR hazard ratio, CI conﬁdence interval, MM RT–PCR multimarker reverse-transcriptase polymerase chain reaction, NA not available
3320 P. Rutkowski et al.target markers, including tyrosinase, MART1, and
uMAGE. Using multimarker assay might increase sensi-
tivity of our test.
42,48 The choice of the set of pigmented
cell-speciﬁc markers for our MM RT-PCR guarantees the
covering the different melanoma cells phenotypes and
comprises the most commonly investigated marker, tran-
scribed actively mainly in melanocytes-tyrosinase,
MART-1 frequently expressed by melanoma cells mainly
in locoregional stage, and uMAGE designed for detection
of MAGE-A1, MAGE-A3, MAGE-A5, MAGE-A6, and
MAGE-A12.
36,43,44,49–51 However, the ﬁnal value of this
test for selecting of patients at higher risk of relapses and
prediction of their prognosis should be conﬁrmed in other
cohort of patients. The results of our study should not be
translated to all populations, because they are based on
the group of relatively advanced primary lesions with
high percentage of ulcerated melanomas and prevalence
of the sentinel nodes metastatic deposits larger than
1 mm.
To summarize, we have demonstrated that SLN tumor
burden categories according Rotterdam criteria and the
positive result of lymph MM-RT-PCR assay had addi-
tional, independent prognostic value in SN-positive
melanoma patients, showing signiﬁcant correlation with
shorter DFS and OS. We suggest including the Rotterdam
criteria for assessment of tumor burden in SNs and RT-
PCR analysis of lymphatic ﬂuid in future clinical trials
involving selective lymphadenectomies in patients with
cutaneous melanoma.
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